港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

54.600

-3.400-5.86%

成交量：71.19万

成交额：3,927.10万

市值：108.65亿

市盈率：-27.19

高：58.300

开：57.750

低：53.800

收：58.000

52周最高：83.600

52周最低：51.600

股本：1.99亿

香港流通股本：1.53亿

量比：1.74

换手率：0.47%

股息：- -

股息率：- -

每股收益(LYR):-2.008

净资产收益率：--

总资产收益率：--

市净率：94.73

市盈率(LYR):-27.19

市销率: - -

数据加载中...

总览公司新闻资讯公告

维立志博：用创新穿越周期

Ofweek光电信息网

维立志博-B09月05日获主力加仓598.4万元

招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级目标价63.5港元

【券商聚焦】招银国际首予维立志博(09887)买入评级目标价80.27港元

招财日报2025.9.4 维立志博首予买入/中国人寿、JS环球业绩点评

维立志博-B09月02日主力净流出138.7万元散户资金买入

维立志博-B大跌5.09% LBL-034 II期试验首例患者近日成功用药

《业绩》维立志博(09887.HK)中期亏损收窄至1.66亿人民币

阿斯达克财经

维立志博-B(09887)公布中期业绩净亏损约1.66亿元同比减少7.8%

维立志博-B08月29日主力净流入1030.9万元散户资金抛售

【IPO前哨】天辰生物赴港：估值超20亿，研发烧钱何时休？

维立志博-B08月26日遭主力抛售1082.8万元

临床开发全面提速！维立志博-B(09887)TCE双抗Ⅰ期疗效比肩CAR-T，Ⅱ期首例患者成功用药

维立志博-B(09887)：LBL-034 II期试验首例患者成功用药

维立志博-B(09887)：稳定价格行动及稳定价格期间结束

中国资产全面爆发！港股打新最高涨近300%

老虎资讯综合

港股异动 | 维立志博(09887)涨超5% 近日奥帕替苏米单抗关键注册临床研究完成全部受试者入组

维立志博-B(09887)因悉数行使超额配股权发行552.93万股

维立志博-B08月11日遭主力抛售527.6万元

累计完成152 起！7月生物医药融资活跃度攀升

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/09887/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":54.6,"timestamp":1763453299006,"preClose":58,"halted":0,"volume":711932,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"收市竞价","change":-3.4,"latestTime":"11-18 16:09:02","open":57.75,"high":58.3,"low":53.8,"amount":39271015,"amplitude":0.077586,"askPrice":54.75,"askSize":400,"bidPrice":54.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1763453400000},"marketStatusCode":4,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":58,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":1.739406,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.739406,"shares":199000000,"dividePrice":0,"high":58.3,"amplitude":0.077586,"preClose":58,"low":53.8,"week52Low":51.6,"pbRate":"94.73","week52High":83.6,"institutionHeld":0,"latestPrice":54.6,"committee":-0.333333,"eps":-2.008042,"divideRate":0,"volume":711932,"delay":0,"ttmEps":-1.858667,"open":57.75,"prevYearClose":35,"prevWeekClose":59,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":59.35,"twentyDayClose":65,"sixtyDayClose":70},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762531200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-17","current":-29.375891,"percent":0.923077,"low":-50.052922,"twenty":-43.982813,"median":-41.479633,"eighty":-37.985718,"high":-34.030535,"avg":-41.267877,"sd":3.199788,"marketCap":11535724400},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-17","current":-36.723723,"twenty":-43.982813,"median":-41.479633,"eighty":-37.985718,"marketCap":11535724400}],"updateTime":1763453342216},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2565246509","title":"维立志博：用创新穿越周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2565246509","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565246509?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 10:24","pubTimestamp":1757298240,"startTime":"0","endTime":"0","summary":"2025年上半年，维立志博在资本市场与临床研发两端均交出了亮眼的成绩单。中信里昂发布研报称偏好维立志博的顶尖抗体药技术，涵盖多个具有占据全球市场实力并有重大突破的创新药技术和分子结构，最新的研发进展和临床数据进一步印证了这个结论。因此，维立志博穿越周期的长期战略落地，背后发人深思。维立志博的科学家们洞察到这一核心痛点，创新性地引入了一个能激活T细胞的激动剂4-1BB。LBL-034代表了维立志博在TCE领域的深度和创新高度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908105045951bba0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908105045951bba0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2565569157","title":"维立志博-B09月05日获主力加仓598.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2565569157","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565569157?lang=zh_cn&edition=fundamental","pubTime":"2025-09-05 16:15","pubTimestamp":1757060119,"startTime":"0","endTime":"0","summary":"09月05日, 维立志博-B股价涨8.76%，报收65.80元，成交金额6388.2万元，换手率0.65%，振幅9.26%，量比1.31。维立志博-B今日主力资金净流入598.4万元，连续3日净流入，上一交易日主力净流入160.8万元。该股近5个交易日下跌0.45%，主力资金累计净流入2077.8万元；近20日主力资金累计净流入1336.6万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905165722a7117fd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250905165722a7117fd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2564325557","title":"招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169589451.USD","ADC.AU","BK4231","09887","BK4023","BK4080","PD","BK7095","ADC","LU1169590202.USD","BK1161"],"gpt_icon":0},{"id":"2564328242","title":"【券商聚焦】招银国际首予维立志博(09887)买入评级 目标价80.27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564328242","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564328242?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 13:44","pubTimestamp":1756964668,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，维立志博 专注于开发以免疫检查点为基础的免疫治疗药物，包括共刺激激动剂和检查点抑制剂，并积极拓展至CD3 T细胞衔接器和ADC等领域。LBL-034是全球临床进展第二快的GPRC5D靶向CD3T细胞衔接器，安全性良好。LBL-034旨在激活GPRC5D表达的肿瘤微环境中的T细胞，有效减少CD3非靶向激活所引发的安全问题。该机构看好公司在PD-L1/4-1BB及T细胞衔接器等下一代免疫治疗领域的布局，基于DCF估值模型给予目标价80.27港元。首次覆盖，给予买入评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1965516","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2564327748","title":"招财日报2025.9.4 维立志博首予买入/中国人寿、JS环球业绩点评","url":"https://stock-news.laohu8.com/highlight/detail?id=2564327748","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564327748?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 11:11","pubTimestamp":1756955495,"startTime":"0","endTime":"0","summary":"同时，LBL-034引发的细胞因子释放水平亦低于TALVEYR。LBL-034的最新数据将于2025年ASH年会公布，公司正在规划相关关键性临床试验。首次覆盖，给予买入评级，目标价为80.27港元。1H25亏损合同确认保险服务费用同比增加33%至150.6亿元，导致2Q25保险服务费用同比上升42%至606亿元人民币。2Q25保险服务业绩为亏损78亿元，同比下跌175%。九阳海外销售跌幅有望逐步收窄，现阶段重心由规模转向利润。我们预计中国小家电行业25年三季度的跌幅已企稳，九阳业务亦一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904111301a4b2ebc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250904111301a4b2ebc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","SG9999012728.SGD","LU1046422090.SGD","SG9999012710.SGD","LU0173614495.USD","01691","BK1521","LU0307460666.USD","BK1550","02628","SG9999012744.USD","SG9999012736.USD","BK1184","IE0032431581.USD","BK1584","09887","LU0588546209.SGD","LU0287142896.SGD"],"gpt_icon":0},{"id":"2564542803","title":"维立志博-B09月02日主力净流出138.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2564542803","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564542803?lang=zh_cn&edition=fundamental","pubTime":"2025-09-02 16:15","pubTimestamp":1756800938,"startTime":"0","endTime":"0","summary":"09月02日, 维立志博-B股价跌4.94%，报收63.50元，成交金额2731.2万元，换手率0.28%，振幅6.51%，量比0.36。维立志博-B今日主力资金净流出138.7万元，上一交易日主力净流入637.7万元。该股近5个交易日下跌3.79%，主力资金累计净流入793.3万元；近20日主力资金累计净流出413.3万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902165954a4af5034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902165954a4af5034&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2564803687","title":"维立志博-B大跌5.09% LBL-034 II期试验首例患者近日成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2564803687","media":"港美通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564803687?lang=zh_cn&edition=fundamental","pubTime":"2025-09-02 11:12","pubTimestamp":1756782771,"startTime":"0","endTime":"0","summary":"9月2日11:03，维立志博-B大幅跳水5.09%，该股报63.400港元，最高报67.450港元，最低报63.400港元，成交量19.04万股，成交额1240.44万港元。消息面上，维立志博-B近日公布了2025年中期业绩，研发成本约1.32亿元，同比增长56.9%;期内亏损约1.66亿元，同比减少7.8%;每股亏损1.06元。此外，维立志博-B近日还宣布，LBL-034I期数据亮眼，II期试验首例患者成功用药，标志着集团LBL-034临床研究取得里程碑成就。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902112029950d934c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902112029950d934c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2563856928","title":"《业绩》维立志博(09887.HK)中期亏损收窄至1.66亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2563856928","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563856928?lang=zh_cn&edition=fundamental","pubTime":"2025-08-31 22:02","pubTimestamp":1756648920,"startTime":"0","endTime":"0","summary":"维立志博－Ｂ(09887.HK) 公布6月止六个月中期业绩，期他收入及收益录得559万人民币(下同)，按年下降4.2%。亏损由上年同期1.8亿元，收窄至1.66亿元，每股亏损1.06元。不派息。上半年，研发成本1.32亿元，增加56.9%。行政开支3,583万元，减少39%。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250721150110069_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1466680/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09887","CNHmain","MUCmain","UCmain","MCNHmain","BK1161","CYB"],"gpt_icon":0},{"id":"2563602123","title":"维立志博-B(09887)公布中期业绩 净亏损约1.66亿元 同比减少7.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563602123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563602123?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 22:03","pubTimestamp":1756476214,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)公布2025年中期业绩，研发成本约1.32亿元，同比增长56.9%;期内亏损约1.66亿元，同比减少7.8%;每股亏损1.06元。公告称，研发成本增长主要由于：(i)CMC开发里程碑开支增加，主要与提交LBL-024的生物制品许可申请(BLA)的筹备工作相关;及(ii)临床开发开支增加，主要由于加快LBL-024及LBL-034的患者入组及临床进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2563073468","title":"维立志博-B08月29日主力净流入1030.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2563073468","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563073468?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 16:15","pubTimestamp":1756455310,"startTime":"0","endTime":"0","summary":"08月29日, 维立志博-B股价涨11.28%，报收66.10元，成交金额7781.2万元，换手率0.80%，振幅12.29%，量比1.20。维立志博-B今日主力资金净流入1030.9万元，上一交易日主力净流出766.1万元。该股近5个交易日下跌1.86%，主力资金累计净流出861.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出518.0万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829171058a4a7524c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829171058a4a7524c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2562218467","title":"【IPO前哨】天辰生物赴港：估值超20亿，研发烧钱何时休？","url":"https://stock-news.laohu8.com/highlight/detail?id=2562218467","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562218467?lang=zh_cn&edition=fundamental","pubTime":"2025-08-27 15:23","pubTimestamp":1756279396,"startTime":"0","endTime":"0","summary":"今年以来，包括药捷安康-B（02617.HK）、维立志博-B（09887.HK）、中慧生物-B（02627.HK）、银诺医药-B（02591.HK）在内的众多生物科技企业通过第18A章登陆了港股市场，其中一些生物科技股在上市后有着非常亮眼的表现。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/a2dd3e09-1100-4ccc-82d8-cbdc3f3e7b19.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/a2dd3e09-1100-4ccc-82d8-cbdc3f3e7b19.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68aeb264230829534078cedd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["AR","02617","02627","09887","BK4213","02591","BK1161"],"gpt_icon":0},{"id":"2562389637","title":"维立志博-B08月26日遭主力抛售1082.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562389637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562389637?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 16:15","pubTimestamp":1756196136,"startTime":"0","endTime":"0","summary":"08月26日, 维立志博-B股价跌2.94%，报收66.00元，成交金额4793.5万元，换手率0.47%，振幅4.56%，量比0.81。维立志博-B今日主力资金净流出1082.8万元，连续4日净流出，上一交易日主力净流出73.0万元。该股近5个交易日下跌10.14%，主力资金累计净流出2569.5万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出4065.6万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826170558a49fb377&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826170558a49fb377&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2562459022","title":"临床开发全面提速！维立志博-B(09887)TCE双抗Ⅰ期疗效比肩CAR-T，Ⅱ期首例患者成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2562459022","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562459022?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 19:08","pubTimestamp":1756120139,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月25日，维立志博-B宣布，公司自主研发的GPRC5D/CD3双特异性抗体顺利完成Ⅱ期临床研究首例患者入组，有望成为首个国产靶向GPRC5D的TCE疗法。LBL-034是一款全球独创2:1结构设计的GPRC5D/CD3双特异性抗体，通过优化抗CD3亲和力和空间位阻作用，显著降低了对T细胞的非特异性激活的风险，同时保持高效的T细胞条件激活能力，从而兼具强大抗肿瘤活性和更佳安全性，具备同类最佳潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4230","CAR","09887","BK4022","BK1161"],"gpt_icon":1},{"id":"2562293248","title":"维立志博-B(09887)：LBL-034 II期试验首例患者成功用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2562293248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562293248?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:29","pubTimestamp":1756117773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，LBL-034(GPRC5D/CD3双特异性抗体)I期数据亮眼，II期试验首例患者成功用药。这标志着集团LBL-034临床研究取得里程碑成就，为推进后续临床试验奠定坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2561469612","title":"维立志博-B(09887)：稳定价格行动及稳定价格期间结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2561469612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561469612?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 18:40","pubTimestamp":1755772837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，有关全球发售的稳定价格期间于2025年8月21日(星期四)结束。于稳定价格期间，稳定价格操作人并无在市场上买卖任何H股以稳定价格。紧随稳定价格期间结束后，公司将继续遵守上市规则第19A.13A条的公众持股量规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1141757368","title":"中国资产全面爆发！港股打新最高涨近300%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141757368","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141757368?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 11:05","pubTimestamp":1755572712,"startTime":"0","endTime":"0","summary":"8月19日，中国资产全面爆发，A股沪指创近10年新高！港股IPO持续势如破竹，7月以来上市12支，首日10支收涨，2支收跌，胜率高达83.33%！累计一手收益可达15,367港元。📢 双登股份（06960）正在火热申购中🔥🚩 申购方式：【老虎国际App】-【持仓】-【IPO】✨ 老虎打新优势：✅ 现金申购0手续费，融资申购0孖展利息✅ 10倍杠杆，额度充足✅ 支持暗盘交易，快人一步抢占先机✅ TOP科技券商，安全可靠","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"中国资产全面爆发！港股打新最高涨近300%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","02627","06960","09887"],"gpt_icon":0},{"id":"2560745809","title":"港股异动 | 维立志博(09887)涨超5% 近日奥帕替苏米单抗关键注册临床研究完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2560745809","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560745809?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 14:34","pubTimestamp":1755498852,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博涨超5%，截至发稿，涨4.54%，报72.5港元，成交额8642.91万港元。消息面上，据维立志博官微消息，8月14日，公司宣布，奥帕替苏米单抗单臂关键注册临床研究已完成全部受试者入组。据介绍，奥帕替苏米单抗是一种PD-L1与4-1BB双靶向双特异性抗体，为全球首款已处于单臂关键性临床阶段的靶向共刺激受体4-1BB的分子，有望成为治疗EP-NEC的首款获批药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":1},{"id":"2558665686","title":"维立志博-B(09887)因悉数行使超额配股权发行552.93万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665686","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558665686?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 17:49","pubTimestamp":1754905773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年8月11日根据悉数行使超额配股权而发行及配发552.93万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1328075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2558658118","title":"维立志博-B08月11日遭主力抛售527.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558658118","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558658118?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 16:15","pubTimestamp":1754900157,"startTime":"0","endTime":"0","summary":"08月11日, 维立志博-B股价跌3.27%，报收66.50元，成交金额8624.9万元，换手率0.85%，振幅7.42%，量比1.04。维立志博-B今日主力资金净流出527.6万元，连续3日净流出，上一交易日主力净流出266.0万元。该股近5个交易日下跌6.99%，主力资金累计净流出463.6万元；近20日主力资金累计净流出572.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811170043a6df4922&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811170043a6df4922&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09887"],"gpt_icon":1},{"id":"2558638949","title":"累计完成152 起！7月生物医药融资活跃度攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2558638949","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558638949?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 09:34","pubTimestamp":1754876074,"startTime":"0","endTime":"0","summary":"2025 年 7 月，全球生物医药领域迎来了融资热潮，交出了一份亮眼的 “成绩单”。数据统计显示，当月共计完成融资活动 152 起，累计公开披露的融资总额超过 43 亿美元，展现出该领域强劲的发展活力与资本吸引力。值得关注的是，在这 26 家企业中，不乏多家国内药企的身影，彰显了中国生物医药企业在创新领域的崛起之势。如橙帆医药7月28日宣布完成超6000万美元的Pre-A+轮融资。维立志博7月25日在香港交易所主板正式挂牌上市，募资总额约1.89亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081109365694dbbc03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081109365694dbbc03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","BK1161","02592"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":152,"code":"91000000","status":"200"}]}}